We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+72.19%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$416M
Cap. Flow
+$154M
Cap. Flow %
13.42%
Top 10 Hldgs %
42.31%
Holding
115
New
23
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.2M
2
APGE icon
Apogee Therapeutics
APGE
+$18.4M
3
ABVX
Abivax
ABVX
+$15.9M
4
SLNO
Soleno Therapeutics
SLNO
+$14.8M
5
CYTK icon
Cytokinetics
CYTK
+$14.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$32M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$12.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$8.84M
4
INZY
Inozyme Pharma
INZY
+$7M
5
VERA icon
Vera Therapeutics
VERA
+$5.59M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
26
DELISTED
Soleno Therapeutics
SLNO
$13.5M 1.18%
+200,000
New +$14.8M
AVTX icon
27
Avalo Therapeutics
AVTX
$957M
$12.8M 1.11%
1,006,217
+398,345
+66% +$3.43M
ESTA icon
28
Establishment Labs
ESTA
$2.75B
$12.7M 1.11%
310,000
-24,863
-7% -$1.02M
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
$12.2M 1.06%
3,924,415
-611,767
-13% -$1.62M
ROIV icon
30
Roivant Sciences
ROIV
$24.5B
$12.1M 1.05%
800,000
+400,000
+100% +$4.95M
TVTX icon
31
Travere Therapeutics
TVTX
$5.16B
$11.9M 1.04%
500,000
-470,000
-48% -$8.84M
DNTH icon
32
Dianthus Therapeutics
DNTH
$5.52B
$10.3M 0.9%
+262,100
New +$6.7M
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.6B
$9.81M 0.85%
3,000,000
+2,800,000
+1,400% +$7.93M
ERAS icon
34
Erasca
ERAS
$6.53B
$9.34M 0.81%
4,285,787
+200,000
+5% +$318K
NRIX icon
35
Nurix Therapeutics
NRIX
$2.36B
$8.94M 0.78%
967,620
– –
VERA icon
36
Vera Therapeutics
VERA
$2.66B
$8.81M 0.77%
303,330
-241,670
-44% -$5.59M
ELVN icon
37
Enliven Therapeutics
ELVN
$3.69B
$8.19M 0.71%
400,000
– –
NAMS icon
38
NewAmsterdam Pharma
NAMS
$3.47B
$7.82M 0.68%
275,000
– –
CLDX icon
39
Celldex Therapeutics
CLDX
$2.78B
$7.76M 0.68%
+300,000
New +$6.95M
PRQR icon
40
ProQR Therapeutics
PRQR
$248M
$7.67M 0.67%
3,600,000
+100,488
+3% +$220K
TARS icon
41
Tarsus Pharmaceuticals
TARS
$2.45B
$7.43M 0.65%
+125,000
New +$6.15M
SMMT icon
42
PUT
Summit Therapeutics
SMMT
$10.5B
$7.23M 0.63%
+350,000
New +$8.49M
AKBA icon
43
Akebia Therapeutics
AKBA
$343M
$6.69M 0.58%
2,450,000
+500,000
+26% +$1.66M
MNPR icon
44
Monopar Therapeutics
MNPR
$709M
$6.49M 0.57%
79,483
+11,983
+18% +$536K
EXEL icon
45
CALL
Exelixis
EXEL
$14B
$6.2M 0.54%
150,000
– –
ZURA icon
46
Zura Bio
ZURA
$500M
$5.52M 0.48%
1,274,351
+1,051,016
+471% +$1.89M
VRDN icon
47
Viridian Therapeutics
VRDN
$2.05B
$5.39M 0.47%
250,000
-140,000
-36% -$2.53M
SVRA icon
48
Savara
SVRA
$1.13B
$5.36M 0.47%
1,500,000
+1,000,000
+200% +$2.96M
NTLA icon
49
CALL
Intellia Therapeutics
NTLA
$1.53B
$5.18M 0.45%
+300,000
New +$3.69M
IMVT icon
50
Immunovant
IMVT
$8.2B
$4.84M 0.42%
+300,000
New +$4.86M
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Affinity Asset Advisors held 115 positions worth $1.15B, up 57% from $732M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $154M of net new capital in Q3 2025, opening 23 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $12.5M trimmed.

  • Affinity Asset Advisors's largest Q3 2025 buy was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q3 2025, an estimated $18.4M increase.
  • Affinity Asset Advisors's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $12.5M.
  • Affinity Asset Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $32M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.15B portfolio in Q3 2025.
  • Affinity Asset Advisors opened 23 new positions and closed 19 in Q3 2025.
  • Affinity Asset Advisors's portfolio value rose 57% quarter-over-quarter to $1.15B.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.